Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2014-06-02 |
Definigen (UK) |
£2.3 million (€2.83 million) |
series A financing round |
Cambridge Enterprise (UK) 24 Haymarket (UK) Dr. Jonathan Milner (UK) Providence Investment Company (UK), Cambridge Capital Group (UK) LBA, Wren Capital (UK), Ranworth Capital (UK) |
|
Series A financing round |
2014-05-30 |
BiolineRx (Israel) |
up to $20 million |
private placement |
Lincoln Park Capital Fund (USA) |
Cancer - Oncology - Infectious diseases - Digestive diseases - Inflammatory diseases - Dermatological diseases - Metabolic diseases |
Private placement |
2014-05-29 |
Epidarex Capital (UK) |
£47.5 million (€58.3 million) |
financing round |
Eli Lilly (USA) King’s College London (UK) European Investment Fund (EU) Scottish Enterprise (UK) Strathclyde Pension Fund (UK), University of Edinburgh (UK) University of Glasgow (UK) University of Aberdeen (UK) |
|
Financing round |
2014-05-28 |
Moberg Pharma (Sweden) |
SEK 60 million (€6.64 million) |
private placement of new shares |
undisclosed Swedish and international institutional qualified investors |
|
Private placement |
2014-05-22 |
Mucosis (The Netherlands) |
up to €5 million |
credit line |
the Netherlands Enterprise Agency (The Netherlands) |
Infectious diseases |
Credit line |
2014-05-21 |
Lysogene (France) |
€16.5 million |
series A financing round |
Bpifrance (France) Novo Seeds (Denmark) Sofinnova Partners (France) |
Rare diseases |
Series A financing round |
2014-05-21 |
Lanthio Pharma (The Netherlands) |
up to €3.6 million |
loan |
Dutch Government agency RVO (The Netherlands) |
Lung diseases |
Loan |
2014-05-13 |
Pledpharma (Sweden) |
SEK 20,25 million (€2.2 million) |
private placement |
|
Cancer - Oncology |
Private placement |
2014-05-08 |
Lophius Biosciences (Germany) |
€2 million |
|
VRD (Germany) - S-Refit (Germany) |
Diagnostic - Infectious diseases - Immunological diseases - Neurodegenerative diseases |
Establishment of a new subsidiary in the EU |
2014-05-08 |
Imaginab (USA - CA) |
$21 Million |
series B financing round |
Mérieux Développement (France) Novartis Venture Funds (Switzerland) Cycad Group (USA) Nextech Invest |
Cancer - Oncology - Autoimmune diseases |
Series B financing round |
2014-05-06 |
Avillion (UK) |
undisclosed |
fundraising |
Royalty Pharma (UK) |
|
Fundraising |
2014-05-05 |
Lundbeck (Denmark) |
|
grant |
The Michael J. Fox Foundation - MJFF (USA) |
Neurodegenerative diseases |
Grant |
2014-05-05 |
Anokion (Switzerland) |
CHF 33 million (€27.1 million) |
series A financing round |
Novartis Venture Fund (Switzerland) Novo Ventures (Denmark) Versant Ventures (USA) |
Allergic diseases - Autoimmune diseases - Immunological diseases |
Series A financing round |
2014-04-30 |
Oxford BioMedica (UK) |
£2.2 million (€2.68 million) |
grant |
BioMedical Catalyst Fund (UK) |
Neurodegenerative diseases |
Grant |
2014-04-30 |
Celenys (France) |
€1 million |
financing round |
Go Capital (France) NCI (France) |
|
Financing round |
2014-04-29 |
Atlas Genetics (UK) |
£16.9 million (€20.59 million) |
series B financing round |
Novartis Venture Funds (Switzerland), Consort Medical (UK), LSP - Life Sciences Partners (The Netherlands), BB Biotech Ventures (Switzerland), Johnson & Johnson Development Corporation (USA), YFM Equity Partners (UK) and private investors |
Diagnostic - Infectious diseases |
Series B financing round |
2014-04-29 |
Skyepharma (UK) |
|
capital increase |
|
|
Capital increase |
2014-04-29 |
Silence Therapeutics (UK) |
£11.4 million |
private placement |
new and existing institutional investors, and certain participating directors |
|
Private placement |
2014-04-28 |
Enterome Bioscience (France) |
€10 million |
series B financing round |
Seventure Partners (France), Lundbeckfond Ventures, Omnes Capital (France) |
Digestive diseases - Inflammatory diseases - Metabolic diseases |
Series B financing round |
2014-04-28 |
SYMPATH consortium (AFFiRiS AG (Austria), Biolution GmbH (Austria), University Hospital Bordeaux (France), INSERM F-CRIN Toulouse (France), Prosenex Ambulatorium Betriebs-GmbH (Austria), Medical University Innsbruck, Department of Neurology (Austria), Forschungszentrum Jülich GmbH (Germany),University Hospital Toulouse (France) ) |
€ 6 million |
grant |
European Commission’s Seventh Framework Program (FP7) |
Neurodegenerative diseases |
Grant |